Assessment of Uterine Access, Uterine Patency and Intrauterine Adhesions Following Endometrial Ablation

Prospective single center observational study. Up to 30 subjects will be enrolled (up to 10 subjects per time point). Patients who sign the Institutional Review Board (IRB) approved consent form who have undergone endometrial ablation within the prior 14 months from time of consent will be asked to participate in this study. Patients meeting all eligibility criteria will undergo either a 3, 6 or 12 month diagnostic second look hysteroscopy (SLH) as assigned by the Investigator depending on the duration of time between the ablation and the signature date of the informed consent (up to 10 subjects for each time point). A diagnostic SLH will be performed for scoring of intrauterine adhesions by the investigator and an independent reviewer. The ability to access the uterine cavity (or not) will be documented.

Inclusion criteria

• Premenopausal female patients ≥ 18 years of age
• Patient has undergone endometrial ablation within the prior 14 months.
• There were no contraindications for endometrial ablation as specified in Ablation System labeling
• Patient agrees to undergo an SLH either at 3, 6 or 12 months post-ablation
• Patient abstained from any form of hormonal contraception including an IUD after the ablation and through the period that the SLH is performed.
• Patient has signed the IRB approved informed consent.

Exclusion criteria

• Additional intrauterine procedures performed between time of endometrial ablation and the SLH; e.g., endometrial and/or myometrial resection.
• IUD in situ
• Pregnant (positive urine pregnancy test) or lactating
• Active sexually transmitted infection or genital infection, or other clinically significant active and/or systemic infection per clinical or laboratory examinations at the time of endometrial ablation procedure or second look hysteroscopy (e.g., cervicitis, vaginitis, endometritis, or salpingitis).
• Systemic steroid within 1 week of endometrial ablation
• Previous adhesiolysis procedure or diagnosis of Asherman's disease.
• No noted clinically significant uterine anomalies at the time of the ablation (e.g., septate uterus or other anomalies that distorts the uterine cavity)
• Any other condition that in the opinion of the investigator could represent an increased risk for the subject, affect the primary outcomes of this study and/or impact the subject's ability to comply with protocol requirements.
• Participating or considering participation in a clinical trial of another investigational drug or device during this study